Table 1 Properties of atypical IκB proteins

Alternative names

B-cell CLL/lymphoma 3 , D19S37, AI528691

Nfkbiz, FLJ30225, FLJ34463, INAP, MAIL, AA408868

Nfkbid, IkB-delta, MGC11314, MGC149503, TA-NFKBH, T-cell activation NFKB-like protein

Ankrd42, FLJ37874, SARP, 4931426M20, 4933417L02Rik

LST1, NF-kappa-B inhibitor-like protein 1

Chromosomal Localisation (NCBI geneID)

Human:

Human:

Human:

Human:

Human:

19q13.1-q13.2

3p12-q12

19q13.12

11q14.1

6p21.3

(602)

(64332)

(84807)

(338699)

(4795)

Mouse:

Mouse:

Mouse:

Mouse:

Mouse:

7A3; 7 9.95 cM

16; 16 C1.2-C1.3

7 B1; 7

7; 7E2

17 B1; 17

(12051)

(80859)

(243910)

(73845)

18.6 cM (18038)

Interaction partners

p50[35, 36, 40], p52[32], c-Jun[41], c-Fos[41], CREB/p300[41, 43], SRC-1[41], B3BP[42], Tip60[43], HDAC-1/-3/-6[37, 45]

p50[64], STAT3[71], FUSS-DDIT3[72], p65[73], RORγ[77], RORα[77]

p50[79], all Rel proteins (GST-pulldown)[78], cRel[80]

p50[87]

Unknown

Tissue specific protein expression

Bone marrow, spleen, lymph nodes, peritoneal lavage, kidney, liver[52]

Heart, skeletal muscle, spleen, kidney, liver, placenta, lung, peripheral blood, leukocytes[73]

Spleen[78]

Brain, lung, kidney, testis, ovary[87]

Human PMBCs[88]

Knockout phenotype

Reduction of Peyer’s Patches[53]. Lack of splenic marginal centers[51].

Dermatitis-like skin irritations[74]. Ocular surface inflammation[76]. Resistant to EAE[77].

Less Treg cells[80].

Unknown

Unknown

Induced via

LPS[39], IL-9[54], IL-4[57]

LPS[61], IL-1[64], BLP[64], PGN[64], MALP[64], Flagellin[64], peptidoglycan[67], β-glucan[67], CpG-DNA[67], IL-18[70], IL-12[70]

LPS[79, 82], CD3[80], anti-IgM[83], CD40[83]

LPS[87], poly(I:C)[87], CpG-DNA[87], zymosan[87]

LPS[88]

Direct target genes (ChIP, pulldown, EMSA)

IP-10[44], IL-10[44], MCP-1[44], CD95[44], CD40[44], IL-23p19[44], CyclinD1[32], TNFα[39], Gata3[55]

IL-6[64], IL8[72], IL-17[77], IFNγ[70]

IL-2[81], IL-6[82], Foxp3[80]

Unknown

Unknown